ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma.International journal of genomics · 2022Article
- CAR T-cells for colorectal cancer immunotherapy: Ready to go?Frontiers in immunology · 2022Review
- Stem Cell-Derived Viral Antigen-Specific T Cells Suppress HIV Replication and PD-1 Expression on CD4+ T Cells.Viruses · 2021Article
- Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors.Frontiers in oncology · 2020Article
- Article
- Article
- Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.Journal of leukocyte biology · 2016Article
- C-Myc regulation by costimulatory signals modulates the generation of CD8+ memory T cells during viral infection.Open biology · 2016Article
- Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.Cell transplantation · 2016Article
- Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation.European journal of immunology · 2013Article
- Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.PloS one · 2013Article
- IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.PloS one · 2010Article
- FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development.Arthritis research & therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Costimulation regulates multiple cellular processes of T cells inducing proliferation, expansion, and survival. The molecular targets of costimulation might then be useful to augment T cell activities. Two defined targets of costimulatory signals in primary T cells are the anti-apoptotic bcl-2 family molecule Bcl-x(L), and survivin, an inhibitor of apoptosis family member that might regulate both cell division and survival. However, the relative importance of, and relationship between, these molecules in primary T cells is not clear. To understand whether they have overlapping or cooperative functions, we used retrovirus-mediated transduction to introduce Bcl-x(L) and survivin separately, or together linked by a 2A picornavirus self-cleaving peptide, into Ag-responding CD8(+) T cells. We found that CD8(+) effector T cells expressing both Bcl-x(L) and survivin strongly expanded at an early stage and had a long-term survival advantage over cells transduced with either molecule alone. In vivo, with response to tumor-expressed Ag following adoptive T cell transfer, Ag-reactive CD8(+) T cells expressing both Bcl-x(L) and survivin displayed greatly enhanced tumor protective activity compared with CD8(+) T cells expressing either molecule introduced separately. These results indicate that Bcl-x(L) and survivin can critically contribute in a cooperative, nonredundant manner to augment the accumulation and persistence of CD8(+) T cells following encounter with Ag. The data provide new insights into why costimulatory signals might need to be sustained over time and suggest a potential novel approach to augment cellular immunotherapy for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.